Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies
A pooled data analysis of two double-blind studies encompassing 1137 episodes of community-acquired pneumonia in hospitalised adults, of which 560 were treated with sparfloxacin and 577 were randomised to comparator antibacterial agents (amoxycillin/clavulanic acid, erythromycin or amoxycillin admin...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 1996-05, Vol.37 (suppl-A), p.73-82 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 82 |
|---|---|
| container_issue | suppl-A |
| container_start_page | 73 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 37 |
| creator | Aubier, M. Lode, H. Gialdroni-Grassi, G. Huchon, G. Hosie, J. Legakis, N. Regamey, C. Segev, S. Vester, R. Wijnands, W. J. Tolstuchow, N. |
| description | A pooled data analysis of two double-blind studies encompassing 1137 episodes of community-acquired pneumonia in hospitalised adults, of which 560 were treated with sparfloxacin and 577 were randomised to comparator antibacterial agents (amoxycillin/clavulanic acid, erythromycin or amoxycillin administered at reference dosages), was performed. The global efficacy rate at the end of treatment in evaluable patients treated with sparfloxacin was 88.3% compared with 84.1% in those who received comparator antibacterial agents. This analysis verified the efficacy of this new aminofluoroquinolone, given orally once daily, in the treatment of community acquired pneumonia. The overall outcome favoured sparfloxacin for use in the empirical treatment of community-acquired pneumonia. |
| doi_str_mv | 10.1093/jac/37.suppl_A.73 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78244257</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78244257</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-2ee371d6d88fd1d268e7cdfbd6f03a4be06be71db7e57bb2eac8af9559b8fa8b3</originalsourceid><addsrcrecordid>eNo9kE1P3DAQhq2qiC60P6CHSj71lsWJk9jbG0UsHwIhUaiqXqyxPRaGJA62I9h_T9CuOI007_OORg8h30u2LNmKHz2COeJimaZx7NTxUvBPZFHWLSsqtio_kwXjrClE3fAv5CClR8ZY27Ryn-xLwUVZiQXBPyNE14VXMH6gLkSaH5DmiJB7HDINjprQ99Pg86YA8zz5iJaOA059GDz8okDHELp5ZyEDhQG6TfLpvZdfAk15sh7TV7LnoEv4bTcPyf369O7kvLi6Obs4Ob4qDBciFxXi_JZtrZTOlrZqJQpjnbatYxxqjazVOANaYCO0rhCMBLdqmpWWDqTmh-Tn9u4Yw_OEKaveJ4NdBwOGKSkhq7quGjGD5RY0MaQU0akx-h7iRpVMvatVs1rFhdqpVYLPnR-745Pu0X40di7nvNjmPmV8_YghPql2Rhp1_u-_Wq9va3b5-1r95W_LgIo4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78244257</pqid></control><display><type>article</type><title>Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Aubier, M. ; Lode, H. ; Gialdroni-Grassi, G. ; Huchon, G. ; Hosie, J. ; Legakis, N. ; Regamey, C. ; Segev, S. ; Vester, R. ; Wijnands, W. J. ; Tolstuchow, N.</creator><creatorcontrib>Aubier, M. ; Lode, H. ; Gialdroni-Grassi, G. ; Huchon, G. ; Hosie, J. ; Legakis, N. ; Regamey, C. ; Segev, S. ; Vester, R. ; Wijnands, W. J. ; Tolstuchow, N.</creatorcontrib><description>A pooled data analysis of two double-blind studies encompassing 1137 episodes of community-acquired pneumonia in hospitalised adults, of which 560 were treated with sparfloxacin and 577 were randomised to comparator antibacterial agents (amoxycillin/clavulanic acid, erythromycin or amoxycillin administered at reference dosages), was performed. The global efficacy rate at the end of treatment in evaluable patients treated with sparfloxacin was 88.3% compared with 84.1% in those who received comparator antibacterial agents. This analysis verified the efficacy of this new aminofluoroquinolone, given orally once daily, in the treatment of community acquired pneumonia. The overall outcome favoured sparfloxacin for use in the empirical treatment of community-acquired pneumonia.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/37.suppl_A.73</identifier><identifier>PMID: 8737127</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adult ; Amoxicillin - therapeutic use ; Amoxicillin-Potassium Clavulanate Combination ; Anti-Bacterial Agents - therapeutic use ; Anti-Infective Agents - therapeutic use ; Clavulanic Acids - therapeutic use ; Community-Acquired Infections - drug therapy ; Community-Acquired Infections - microbiology ; Double-Blind Method ; Drug Therapy, Combination - therapeutic use ; Erythromycin - therapeutic use ; Fluoroquinolones ; Humans ; Microbial Sensitivity Tests ; Penicillins - therapeutic use ; Pneumonia, Bacterial - drug therapy ; Pneumonia, Bacterial - microbiology ; Quinolones - therapeutic use ; Streptococcus pneumoniae - drug effects</subject><ispartof>Journal of antimicrobial chemotherapy, 1996-05, Vol.37 (suppl-A), p.73-82</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-2ee371d6d88fd1d268e7cdfbd6f03a4be06be71db7e57bb2eac8af9559b8fa8b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8737127$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aubier, M.</creatorcontrib><creatorcontrib>Lode, H.</creatorcontrib><creatorcontrib>Gialdroni-Grassi, G.</creatorcontrib><creatorcontrib>Huchon, G.</creatorcontrib><creatorcontrib>Hosie, J.</creatorcontrib><creatorcontrib>Legakis, N.</creatorcontrib><creatorcontrib>Regamey, C.</creatorcontrib><creatorcontrib>Segev, S.</creatorcontrib><creatorcontrib>Vester, R.</creatorcontrib><creatorcontrib>Wijnands, W. J.</creatorcontrib><creatorcontrib>Tolstuchow, N.</creatorcontrib><title>Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>A pooled data analysis of two double-blind studies encompassing 1137 episodes of community-acquired pneumonia in hospitalised adults, of which 560 were treated with sparfloxacin and 577 were randomised to comparator antibacterial agents (amoxycillin/clavulanic acid, erythromycin or amoxycillin administered at reference dosages), was performed. The global efficacy rate at the end of treatment in evaluable patients treated with sparfloxacin was 88.3% compared with 84.1% in those who received comparator antibacterial agents. This analysis verified the efficacy of this new aminofluoroquinolone, given orally once daily, in the treatment of community acquired pneumonia. The overall outcome favoured sparfloxacin for use in the empirical treatment of community-acquired pneumonia.</description><subject>Adult</subject><subject>Amoxicillin - therapeutic use</subject><subject>Amoxicillin-Potassium Clavulanate Combination</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Clavulanic Acids - therapeutic use</subject><subject>Community-Acquired Infections - drug therapy</subject><subject>Community-Acquired Infections - microbiology</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination - therapeutic use</subject><subject>Erythromycin - therapeutic use</subject><subject>Fluoroquinolones</subject><subject>Humans</subject><subject>Microbial Sensitivity Tests</subject><subject>Penicillins - therapeutic use</subject><subject>Pneumonia, Bacterial - drug therapy</subject><subject>Pneumonia, Bacterial - microbiology</subject><subject>Quinolones - therapeutic use</subject><subject>Streptococcus pneumoniae - drug effects</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1P3DAQhq2qiC60P6CHSj71lsWJk9jbG0UsHwIhUaiqXqyxPRaGJA62I9h_T9CuOI007_OORg8h30u2LNmKHz2COeJimaZx7NTxUvBPZFHWLSsqtio_kwXjrClE3fAv5CClR8ZY27Ryn-xLwUVZiQXBPyNE14VXMH6gLkSaH5DmiJB7HDINjprQ99Pg86YA8zz5iJaOA059GDz8okDHELp5ZyEDhQG6TfLpvZdfAk15sh7TV7LnoEv4bTcPyf369O7kvLi6Obs4Ob4qDBciFxXi_JZtrZTOlrZqJQpjnbatYxxqjazVOANaYCO0rhCMBLdqmpWWDqTmh-Tn9u4Yw_OEKaveJ4NdBwOGKSkhq7quGjGD5RY0MaQU0akx-h7iRpVMvatVs1rFhdqpVYLPnR-745Pu0X40di7nvNjmPmV8_YghPql2Rhp1_u-_Wq9va3b5-1r95W_LgIo4</recordid><startdate>19960501</startdate><enddate>19960501</enddate><creator>Aubier, M.</creator><creator>Lode, H.</creator><creator>Gialdroni-Grassi, G.</creator><creator>Huchon, G.</creator><creator>Hosie, J.</creator><creator>Legakis, N.</creator><creator>Regamey, C.</creator><creator>Segev, S.</creator><creator>Vester, R.</creator><creator>Wijnands, W. J.</creator><creator>Tolstuchow, N.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960501</creationdate><title>Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies</title><author>Aubier, M. ; Lode, H. ; Gialdroni-Grassi, G. ; Huchon, G. ; Hosie, J. ; Legakis, N. ; Regamey, C. ; Segev, S. ; Vester, R. ; Wijnands, W. J. ; Tolstuchow, N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-2ee371d6d88fd1d268e7cdfbd6f03a4be06be71db7e57bb2eac8af9559b8fa8b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Amoxicillin - therapeutic use</topic><topic>Amoxicillin-Potassium Clavulanate Combination</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Clavulanic Acids - therapeutic use</topic><topic>Community-Acquired Infections - drug therapy</topic><topic>Community-Acquired Infections - microbiology</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination - therapeutic use</topic><topic>Erythromycin - therapeutic use</topic><topic>Fluoroquinolones</topic><topic>Humans</topic><topic>Microbial Sensitivity Tests</topic><topic>Penicillins - therapeutic use</topic><topic>Pneumonia, Bacterial - drug therapy</topic><topic>Pneumonia, Bacterial - microbiology</topic><topic>Quinolones - therapeutic use</topic><topic>Streptococcus pneumoniae - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aubier, M.</creatorcontrib><creatorcontrib>Lode, H.</creatorcontrib><creatorcontrib>Gialdroni-Grassi, G.</creatorcontrib><creatorcontrib>Huchon, G.</creatorcontrib><creatorcontrib>Hosie, J.</creatorcontrib><creatorcontrib>Legakis, N.</creatorcontrib><creatorcontrib>Regamey, C.</creatorcontrib><creatorcontrib>Segev, S.</creatorcontrib><creatorcontrib>Vester, R.</creatorcontrib><creatorcontrib>Wijnands, W. J.</creatorcontrib><creatorcontrib>Tolstuchow, N.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aubier, M.</au><au>Lode, H.</au><au>Gialdroni-Grassi, G.</au><au>Huchon, G.</au><au>Hosie, J.</au><au>Legakis, N.</au><au>Regamey, C.</au><au>Segev, S.</au><au>Vester, R.</au><au>Wijnands, W. J.</au><au>Tolstuchow, N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>1996-05-01</date><risdate>1996</risdate><volume>37</volume><issue>suppl-A</issue><spage>73</spage><epage>82</epage><pages>73-82</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><abstract>A pooled data analysis of two double-blind studies encompassing 1137 episodes of community-acquired pneumonia in hospitalised adults, of which 560 were treated with sparfloxacin and 577 were randomised to comparator antibacterial agents (amoxycillin/clavulanic acid, erythromycin or amoxycillin administered at reference dosages), was performed. The global efficacy rate at the end of treatment in evaluable patients treated with sparfloxacin was 88.3% compared with 84.1% in those who received comparator antibacterial agents. This analysis verified the efficacy of this new aminofluoroquinolone, given orally once daily, in the treatment of community acquired pneumonia. The overall outcome favoured sparfloxacin for use in the empirical treatment of community-acquired pneumonia.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>8737127</pmid><doi>10.1093/jac/37.suppl_A.73</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 1996-05, Vol.37 (suppl-A), p.73-82 |
| issn | 0305-7453 1460-2091 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78244257 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Free Full-Text Journals in Chemistry |
| subjects | Adult Amoxicillin - therapeutic use Amoxicillin-Potassium Clavulanate Combination Anti-Bacterial Agents - therapeutic use Anti-Infective Agents - therapeutic use Clavulanic Acids - therapeutic use Community-Acquired Infections - drug therapy Community-Acquired Infections - microbiology Double-Blind Method Drug Therapy, Combination - therapeutic use Erythromycin - therapeutic use Fluoroquinolones Humans Microbial Sensitivity Tests Penicillins - therapeutic use Pneumonia, Bacterial - drug therapy Pneumonia, Bacterial - microbiology Quinolones - therapeutic use Streptococcus pneumoniae - drug effects |
| title | Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T08%3A36%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sparfloxacin%20for%20the%20treatment%20of%20community-acquired%20pneumonia:%20a%20pooled%20data%20analysis%20of%20two%20studies&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Aubier,%20M.&rft.date=1996-05-01&rft.volume=37&rft.issue=suppl-A&rft.spage=73&rft.epage=82&rft.pages=73-82&rft.issn=0305-7453&rft.eissn=1460-2091&rft_id=info:doi/10.1093/jac/37.suppl_A.73&rft_dat=%3Cproquest_cross%3E78244257%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78244257&rft_id=info:pmid/8737127&rfr_iscdi=true |